NCT00302081View on ClinicalTrials.gov

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

PHASE3CompletedINTERVENTIONAL
Enrollment

696

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Hepatitis C, Chronic
Interventions
BIOLOGICAL

peginterferon alfa-2b (SCH 54031)

1.5 mcg/kg QW SC for 24 weeks

BIOLOGICAL

peginterferon alfa-2b (SCH 54031)

1.0 mcg/kg QW SC for 24 weeks

BIOLOGICAL

peginterferon alfa-2b (SCH 54031)

1.5 mcg/kg QW SC for 16 weeks

DRUG

ribavirin (SCH 18908)

800-1200 mg daily for 24 weeks

DRUG

ribavirin (SCH 18908)

800-1200 mg daily for 16 weeks

Sponsors
All Listed Sponsors
collaborator

Integrated Therapeutics Group

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00302081 - Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) | Biotech Hunter | Biotech Hunter